Key Highlights

  • Annexon shares closed up 17% at $6.50 after announcing it will present post hoc analyses from its Phase 2 ARCHER trial at the ASRS Annual Scientific Meeting.
  • The presentation will highlight baseline characteristics correlated with a confirmed loss of 15 letters in Best Corrected Visual Acuity (BCVA) among geographic atrophy patients.
  • These findings are intended to refine patient selection strategies for the ongoing Phase 3 ARCHER II clinical trial.
  • Annexon remains on track to report pivotal topline data for vonaprument in geographic atrophy during the fourth quarter of 2026.

Annexon, Inc. (NASDAQ: ANNX) shares rose 17% to close at $6.50 after the company announced it will present post hoc analyses from its Phase 2 ARCHER trial at the American Society of Retina Specialists (ASRS) Annual Scientific Meeting, offering the retina specialist community new insight into patient-level factors associated with disease progression in geographic atrophy ahead of the company's pivotal Phase 3 data later this year.

The presentation will specifically highlight baseline characteristics correlated with a confirmed loss of 15 letters in Best Corrected Visual Acuity (BCVA) among patients with geographic atrophy. BCVA is a standard clinical measure of vision quality used extensively in ophthalmology trials, and a 15-letter loss represents a clinically meaningful decline in visual function, making this analysis directly relevant to understanding which patients are most likely to experience significant vision deterioration.

Post hoc analyses of this kind, examining data after a trial's primary endpoints have already been assessed, are commonly used to generate hypotheses about which patient subgroups may derive the greatest benefit from a given therapy, or in this case, which baseline characteristics are most predictive of disease progression risk. While such analyses are exploratory in nature and carry less statistical weight than pre-specified primary endpoints, they can provide valuable clinical and trial-design insight.

Annexon has stated that these findings are intended to refine patient selection strategies for the ongoing Phase 3 ARCHER II clinical trial. By better understanding which baseline patient characteristics correlate with faster or more severe vision loss, the company and independent investigators may be able to more precisely identify and enroll patients most likely to benefit from ANX007 (vonaprument) in future clinical and, eventually, real-world treatment settings.

Today's rally likely reflects investor anticipation building ahead of the more consequential catalyst still to come: Annexon remains on track to report pivotal topline data for vonaprument in geographic atrophy during the fourth quarter of 2026. The ASRS presentation serves as an interim data point that reinforces confidence in the underlying trial design and patient stratification approach heading into that more decisive readout.

For a company whose valuation is closely tied to the binary outcome of its Phase 3 ARCHER II data, today's positive reaction to what is fundamentally supplementary, exploratory data suggests investors are using every available data point to build conviction ahead of the fourth-quarter readout, with the refined patient selection methodology potentially improving the statistical odds of a successful pivotal trial outcome.